REG - Hemogenyx Pharma Plc - Placing to Raise £250,000 and Director’s Dealing

Hemogenyx PharmaceuticalsAnnouncement

Tue 08:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250729:nRSc8992Sa&default-theme=true

RNS Number : 8992S  Hemogenyx Pharmaceuticals PLC  29 July 2025

   29 July 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Hemogenyx Secures £250,000 to continue its Phase 1 Clinical Trials

And

Director's Dealing

Introduction

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has
raised gross proceeds of £250,000 via an allotment to Vladislav Sandler of
133,690 new ordinary shares of £0.01 each ("New Ordinary Shares") at an issue
price of 187p, representing a premium to the present market price (the "Issue
Price").

The net proceeds of this fundraise will be dedicated to the continuation of
the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell
therapy ("HG-CT-1"), aimed at treating relapsed/refractory acute myeloid
leukemia in adults ("R/R AML"). As shareholders will be aware, the first two
patients have now been treated with HG-CT-1 with the four-week safety trials
successfully completed and with encouraging early signs of efficacity.

Issuance of the New Ordinary Shares

The Company is currently unable to issue and admit New Ordinary Shares without
either the publication of an FCA approved prospectus or relying upon an
exemption to the requirement to issue a prospectus.

Consequently, this fundraise involves the agreement by Vladislav Sandler, CEO
and director of the Company, to subscribe for the New Ordinary Shares at the
Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and
1(5) (h) of the UK Prospectus Regulation.

Following allotment of the New Ordinary Shares, Vladislav Sandler has agreed
to direct their issue to a small group of individual investors who made an
approach wishing to make a new investment in the Company; they will acquire
the Subscription Shares from Mr Sandler at the price of 187p per share.

Warrants

Concurrent with the purchase of the New Ordinary Shares, the new investor
group will receive warrants from the Company on a one-for-one basis. These
warrants will be exercisable for a period of 36 months at an exercise price of
187p  ("Exercise Price"), subject to adjustment in certain circumstances as
set out in the warrant instrument including a reset of the Exercise Price if
the Company completes a share issuance (or other transaction granting rights
to subscribe for equity securities) during the Exercise Period at a price
lower than the Exercise Price.

Total Voting Rights

Application will be made for the 133,690 New Ordinary Shares, which will
rank pari passu in all respects with the existing Ordinary Shares of the
Company, to be admitted to the FCA official list and to trading on the equity
shares (transition) category of the Official List maintained by the FCA and to
trading on the main market for listed securities of the LSE, which is expected
to occur on or around 8.00 a.m. on 7 August 2025 ("Admission").

Upon Admission, the total number of issued shares and the total number of
voting rights in the Company will be 4,727,229.

The above figure of 4,727,229 should be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.

The Company will keep the market informed of future developments as trials
proceed.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented:
"We are pleased to have attracted funding from this group of investors at a
premium to the current price - this reflects their confidence in the progress
made by the Company to date and in the long-term prospects of Hemogenyx. The
fact that the raise was completed at a premium to the market price
demonstrates this confidence and shows that they see considerable  upside
potential in our share price as we advance HG-CT-1 through clinical
development. ."

UK Market Abuse Regulation (UK MAR) Disclosure

Certain information contained in this announcement would have been inside
information for the purposes of Article 7 of Regulation No 596/2014 (as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement. The person responsible for
arranging for the release of this announcement on behalf of Hemogenyx
Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer &
Co-Founder.

 

Director's Dealing Notification

 1.  Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Vladislav Sandler
 2.  Reason for the Notification
 a)  Position/status                                              PDMR

 b)  Initial notification / Amendment                             Initial notification

 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Hemogenyx Pharmaceuticals plc

 b)  LEI                                                          2138008L93GYU5GN6179

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Ordinary Shares of £0.01
     Identification Code                                          GB00BQVXM815

 b)  Nature of the transaction                                    Off Market Allotment

 c)  Price(s) and volume(s)                                       Price(s)                        Volume(s)

                                                                  187  pence per Ordinary Share    133,690 Ordinary Shares
 d)  Aggregated information:

     Aggregated volume                                             133,690 Ordinary Shares

     Price                                                        187 pence per Ordinary Share

 e)  Date of the transaction                                        29 July 2025

 f)  Place of the transaction                                     London

d)

Aggregated information:

Aggregated volume

Price

 

 133,690 Ordinary Shares

187 pence per Ordinary Share

 

 

e)

Date of the transaction

  29 July 2025

 

f)

Place of the transaction

London

 

Enquiries:

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City .

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as platform technologies that it uses as engines for novel
product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEPPUQPMUPAUUB